Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 1/2001

01-01-2001 | Current Opinion

The Star Systems

Overview and Use In Determining Antiepileptic Drug Choice

Authors: Prof. Martin J. Brodie, Patrick Kwan

Published in: CNS Drugs | Issue 1/2001

Login to get access

Abstract

An explosion in antiepileptic drug (AED) therapy began in the 1990s with the licensing of 9 new chemical entities and more to come. Important differences between AEDs may not be detected by regulatory trials, which are designed to satisfy licensing requirements and often diverge considerably from everyday clinical practice. The Star Systems have been developed as evidence-based yet pragmatic and flexible models for comparing AEDs.
Each drug has been judged across a range of criteria, including mechanism of action, pharmacokinetics, ease of use, efficacy, tolerability, safety, interaction profile and a ‘comfort factor’. A score has been allocated under each category and systems have been devised for patients with newly diagnosed epilepsy and those with difficult-to-control seizures requiring combination therapy.
The choice of treatment should involve assessment of patient-related factors, accurate classification of seizure type and syndrome, married with an understanding of the pharmacology of the AEDs. A staged management plan should be formulated when initiating treatment with the aim of preventing the development of refractory epilepsy. When using combinations of AEDs, the mechanism of action of each agent should be taken into consideration.
Such an individualised approach to management will optimise the chance of attaining remission and help many more patients achieve a fulfilling life.
Literature
1.
Brodie MJ, Shorvon SD, Canger R, et al. Commission on European Affairs: appropriate standards of epilepsy care across Europe. Epilepsia 1997; 38: 1245–50PubMedCrossRef
2.
3.
Temkin O. The falling sickness: a history of epilepsy from the Greeks to the beginnings of modern neurology. Baltimore: Johns Hopkins, 1971
4.
5.
6.
Chadwick D. Monotherapy clinical trials of new antiepileptic drugs: design, indications and controversies. Epilepsia 1997; 38 Suppl. 9: 16–20CrossRef
7.
Brodie MJ. Monostars: an aid to choosing an antiepileptic drug as monotherapy. Epilepsia 1999; 40 Suppl. 6: 17–22CrossRef
8.
Brodie MJ. Lamotrigine versus other antiepileptic drugs: a star rating system is born. Epilepsia 1994; 35 Suppl. 5: 41–6CrossRef
9.
Brodie MJ, Kwan P. Effectiveness of first ever antiepileptic drug [abstract]. Epilepsia 2000; 41 Suppl. 7: 89
10.
11.
Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalised tonic-clonic seizures. N Engl J Med 1985; 313: 145–51PubMedCrossRef
12.
13.
14.
Kalvaianen R, Nousiainen I, Mantyjarvi M, et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 1999; 53: 922–6CrossRef
15.
White HS. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia 1999; 40 Suppl. 5: 2–10CrossRef
16.
Brodie MJ, Mumford JP, 012 Study Group. Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy. Epilepsy Res 1999; 34: 199–205PubMedCrossRef
17.
Leach JP. Polypharmacy with anticonvulsants: focus on synergy. CNS Drugs 1997; 8: 366–75CrossRef
18.
Cereghino JJ, Brock JT, Van Meter JC, et al. The efficacy of carbamazepine combinations in epilepsy. Clin Pharmacol Ther 1975; 18: 733–41PubMed
19.
20.
Stolarek I, Blacklaw J, Forrest G, et al. Vigabatrin and lamotrigine in refractory epilepsy. J Neurol Neurosurg Psychiatry 1994; 57: 921–4PubMedCrossRef
21.
Brodie MJ, Yuen AWC, 105 Study Group. Lamotrigine substitution study: evidence for synergism with sodium valproate? Epilepsy Res 1997; 26: 423–32PubMedCrossRef
22.
Stephen LJ, Sills GJ, Brodie MJ. Lamotrigine and topiramate may be a useful combination. Lancet 1998; 351: 958–9PubMed
23.
Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on? Seizure 2000; 9: 464–8PubMedCrossRef
24.
Brodie MJ. Management strategies for refractory localisation-related seizures. Epilepsia. In press
25.
Pisani F, Oteri G, Russo MF, et al. Efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 1999; 40: 1141–6PubMedCrossRef
26.
Brodie MJ. Drug interactions and epilepsy. Epilepsia 1992; 33 Suppl. 1: 13–22CrossRef
27.
Callaghan N, Kenny RA, O’Neill B, et al. A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. J Neurol Neurosurg Psychiatry 1985; 48: 639–44PubMedCrossRef
28.
Mattson RH, Cramer JA, Collins JF, et al. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992; 327: 765–71PubMedCrossRef
29.
Richens A, Davidson DLW, Cartlidge NEF, et al. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. J Neurol Neurosurg Psychiatry 1994; 57: 682–7PubMedCrossRef
30.
Heller AJ, Ring HA, Reynolds EH. Factors relating to dramatic response to clobazam therapy in refractory epilepsy. Epilepsy Res 1988; 2: 276–80PubMedCrossRef
31.
De Silva M, MacArdle B, McGowan M, et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996; 347: 709–13PubMedCrossRef
32.
Brodie MJ, Richens A, Yuen AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995; 345: 476–9PubMedCrossRef
33.
Bill PA, Vigonius V, Pohlmann H, et al. A double-blind controlled trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997; 27: 195–204PubMedCrossRef
34.
Guerreiro MM, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997; 27: 205–13PubMedCrossRef
35.
Christie W, Kramer G, Vigonius U, et al. A double-blind controlled clinical trial of oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997; 26: 451–60CrossRef
36.
Chadwick DW, Anhut H, Greiner MJ, et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. Neurology 1998; 51: 1282–8PubMedCrossRef
37.
Brodie MJ, Overstall PW, Giorgi L, et al. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsy Res 1999; 37: 81–7PubMedCrossRef
38.
Brodie MJ, Anhut H, Murray G, et al. Gabapentin versus lamotrigine monotherapy: a double-blind comparison. Epilepsia 2000; 41 Suppl. Florence: 138–9
39.
Marson AG, Kadir ZA, Hutton JL, et al. The new antiepileptic drugs: a systemic review of their efficacy and tolerability. Epilepsia 1997; 38: 859–80PubMedCrossRef
40.
41.
Rowan AJ, Meijer JWA, de Beer-Pawlikowski N, et al. Valproate ethosuximide combination therapy for refractory absence seizures. Arch Neurol 1983; 40: 797–802PubMedCrossRef
42.
Schapel GJ, Black AB, Lam EL, et al. Combination vigabatrin and lamotrigine therapy for intractable epilepsy. Seizure 1996; 5: 51–6PubMedCrossRef
43.
Devinsky O. Cognitive and behavioral effects of antiepileptic drugs. Epilepsia 1995; 36 Suppl. 3: 46–52CrossRef
44.
Devinsky O, Vazquez B. Behavioral changes associated with epilepsy. Neurol Clin 1993; 11: 127–49PubMed
45.
Isojärvi JIT, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993; 329: 1383–8PubMedCrossRef
46.
Isojärvi JIT, Rättyä J, Myllylä VV, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998; 43: 446–51PubMedCrossRef
47.
Sankar R, Wasterlain CG. Is the devil we know the lesser of two evils? Vigabatrin and visual fields. Neurology 1999; 52: 1537–8PubMedCrossRef
48.
Yerby MS. Contraception, pregnancy and lactation in women with epilepsy. In: Brodie MJ, Treiman DM, editors. Modern management of epilepsy. London: Balliere’s Clinical Neurology, 1996: 887–908
49.
Morrell MJ. The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy and fetal outcome. Epilepsia 1996; 37 Suppl. 6: S34–44PubMedCrossRef
50.
Crawford P, Appleton R, Betts T, et al. Best practice guidelines for the management of women with epilepsy. Seizure 1999; 8: 201–17PubMedCrossRef
51.
Patsalos PN, Duncan JS. Antiepileptic drugs: a review of clinically significant drug interactions. Drug Saf 1993; 9: 156–84PubMedCrossRef
52.
Thomson AH, Brodie MJ. Pharmacokinetic optimisation of anticonvulsant therapy. Clin Pharmacokinet 1992; 23: 216–30PubMedCrossRef
53.
Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Lancet 1999; 354: 13–9PubMedCrossRef
54.
Dreifuss FE, Santilli N, Langer DH, et al. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987; 37: 379–85PubMedCrossRef
55.
McKee PJW, Brodie MJ. Pharmacokinetic interactions with anticonvulsant drugs. In: Trimble MR, editor. New anticonvulsants: advances in the treatment of epilepsy. London: John Wiley & Sons, 1994: 1–33
56.
Heller AJ, Chesterman P, Elwes RDC, et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. J Neurol Neurosurg Psychiatry 1995; 58: 44–50PubMedCrossRef
57.
Feely M, Gibson J. Intermittent clobazam for catamenial epilepsy: tolerance avoided. J Neurol Neurosurg Psychiatry 1984; 27: 1279–82CrossRef
58.
Hannah JA, Brodie MJ. Epilepsy and learning disabilities: a challenge for the next millenium. Seizure 1998; 7: 3–13PubMedCrossRef
59.
Brodie MJ. Lamotrigine: an update. Can J Neurol Sci 1996; 23 Suppl. 2: 6–9
60.
Steiner TJ, Dellaportas CI, Findley LJ, et al. Lamotrigine mono-therapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999; 40: 601–7PubMedCrossRef
61.
Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999; 40: 985–91PubMedCrossRef
62.
63.
Gee NS, Brown JP, Dissanaya KE, et al. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha 2 delta subunit of a calcium channel. J Biol Chem 1996; 271: 5768–76PubMedCrossRef
64.
DeToledo JC, Toledo C, Decorle JD, et al. Changes in body weight with chronic high dose gabapentin therapy. Ther Drug Monit 1997; 19: 394–6PubMedCrossRef
65.
Dam M, Ekberg R, Loyning Y, et al. A double-blind study comparing oxcarbazepine and carbamazepin in patients with newly diagnosed previously untreated epilepsy. Epilepsy Res 1989; 3: 70–6PubMedCrossRef
66.
67.
Fattore C, Cipolla G, Gatti G, et al. Induction of ethinyloestradiol and levonorgestrel metabolism by oxcabazepine in healthy women. Epilepsia 1999; 40: 783–7PubMedCrossRef
68.
Friis ML, Kristensen O, Boas J, et al. Therapeutic experiences with 947 epileptic outpatients in oxcarbazepine treatment. Acta Neurol Scand 1993; 87: 224–7PubMedCrossRef
69.
Stephen LJ, Sills GJ, Brodie MJ. Topiramate in refractory epilepsy: a prospective observational study. Epilepsia 2000; 41: 977–80PubMedCrossRef
70.
Rosenfeld WE, Doose DR, Walker SA, et al. Effect of topiramate on the pharmackinetics of an oral contraceptive containing norethindrone and ethinyloestradiol in patients with epilepsy. Epilepsia 1997; 38: 317–23PubMedCrossRef
71.
72.
Wilson EA, Brodie MJ. New antiepileptic drugs. In: Brodie MJ, Treiman DM, editors. Modern management of epilepsy. Bailliere’s Clinical Neurology. London: Bailliere Tindall, 1996: 723–47
Metadata
Title
The Star Systems
Overview and Use In Determining Antiepileptic Drug Choice
Authors
Prof. Martin J. Brodie
Patrick Kwan
Publication date
01-01-2001
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 1/2001
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200115010-00001

Other articles of this Issue 1/2001

CNS Drugs 1/2001 Go to the issue

Review Article

The Economics of Selective Serotonin Reuptake Inhibitors In Depression

Therapy in Practice

Compulsive Buying Disorder

Review Article

Glutamate Receptors and Nociception

Commentary

The Star Systems